Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Business Wire•04/11/2026•06:57 ET
2
Key Highlights
- ➤Alto granted a new employee an option to purchase 50,000 shares.
- ➤Option exercise price is $22.70, matching Alto’s closing price on grant date.
- ➤Option vests over four years, with 25% vesting after one year.
- ➤Option carries a 10-year term under Alto’s 2025 Inducement Plan.
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on November 3, 2026, the Compensation and Management Development Committee of Alto’s Board of Directors granted a new employee an option to purchase 50,000 shares of Alto’s common stock. The stock option was granted under Alto’s 2025 Inducement Plan as a material inducement to the individual entering employment with Alto in accordance with NYSE Listed Company Manual Rule 303A.08.
Get started
Create a free account to read the full story.